This series of tweets will be about key trials studying SGLT-2 inhibitors in heart failure. While initially studied for DM, these meds were shown to improve CV outcomes in CHF patients, regardless of DM status.
1) DAPA-HF trial:
Among patients with a reduced EF, the risk of worsening heart failure or death from CV causes was lower among those who received dapagliflozin vs placebo.
2) DELIVER trial:
Dapagliflozin reduced the combined risk of worsening heart failure or CV death in patients with heart failure and a mildly reduced or preserved EF.
Among patients with heart failure and LVEF < 40%, those in the empagliflozin group had a lower risk of CV death or hospitalization for HF than those in the placebo group, regardless of diabetes status.
Empagliflozin reduced the combined risk of CV death or hospitalization for heart failure in patients with heart failure and a preserved EF, regardless of the presence or absence of diabetes
In patients with DM and worsening HF, sotagliflozin therapy resulted in significantly fewer deaths from CV causes and hospitalizations and urgent visits for heart failure than placebo.
These trials opened up an important avenue of management for heart failure. If you know of other RCTs for SGLT-2 inhibitors in heart failure patients then please share!
• • •
Missing some Tweet in this thread? You can try to
force a refresh